Adjuvant Radiation Therapy For Wedge-Resected Non-Small Cell Lung Cancer Adjacent To A Large Thoracic Aortic Aneurysm: A Case Report And Review Of The Literature

10.5580/2a8a ◽  
2012 ◽  
Vol 8 (2) ◽  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Case Report ◽  
Aortic Aneurysm ◽  
Thoracic Aortic Aneurysm ◽  
Small Cell ◽  
Adjuvant Radiation ◽  
Review Of The Literature ◽  
Small Cell Lung ◽  
Adjuvant Radiation Therapy

Adjuvant Radiation Therapy After Complete Resection of Non–Small-Cell Lung Cancer

2002 ◽  
Vol 20 (5) ◽  
pp. 1427-1429
Author(s):  
Eric Vallières ◽  
Mitchell Machtay ◽  
Eli Glatstein ◽  
James A. Bonner
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Resection ◽  
Small Cell ◽  
Adjuvant Radiation ◽  
Small Cell Lung ◽  
Adjuvant Radiation Therapy

Timing of adjuvant radiation therapy and survival outcomes after surgical resection of intracranial non-small cell lung cancer metastases

2019 ◽  
Vol 183 ◽  
pp. 105389
Author(s):  
John P. Sheppard ◽  
Giyarpuram N. Prashant ◽  
Cheng Hao Jacky Chen ◽  
Sophie Peeters ◽  
Carlito Lagman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Surgical Resection ◽  
Small Cell ◽  
Survival Outcomes ◽  
Adjuvant Radiation ◽  
Small Cell Lung ◽  
Adjuvant Radiation Therapy ◽  
Cancer Metastases

scholarly journals SURG-04. Surgical resection of symptomatic brain metastasis in patients with non-small cell lung cancer irrespective from lesion count

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii24-iii24
Author(s):  
Stephanie T Jünger ◽  
David Reinecke ◽  
Anna-Katharina Meißner ◽  
Roland Goldbrunner ◽  
Stefan Grau
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Systemic Treatment ◽  
Small Cell ◽  
Adjuvant Radiation ◽  
Lesion Count ◽  
Small Cell Lung ◽  
Adjuvant Radiation Therapy ◽  
Adjuvant Systemic Treatment

Abstract Background and Purpose Current guidelines primarily suggest the resection in case of a limited number of brain metastases (BM). With an increasing number of local and systemic treatment options this approach needs reconsideration. Therefore, we aimed to evaluate the role of metastectomy in patients with non-small cell lung cancer (NSCLC) treated in a comprehensive setting disregarding lesion count. Patients and Methods In this monocentric retrospective analysis, patients receiving surgery for 1–3 BM with available demographic, clinical, and tumor-associated parameters were included. Prognostic factors for local control (LC) and overall survival (OS) were analyzed by Log rank test and Cox proportional hazards. Results Two-hundred-sixteen patients were included: 129 (59.7%) with single/solitary, 64 (29.6%) with 2–3, and 23 (10.6%) with more than three BM. Resection of the symptomatic BM(s) improved the patients’ Karnofsky performance index (KPI) significantly (p<0.001), enabling adjuvant radiotherapy in 199 (92.1%) and systemic treatment in 119 (55.1%) patients. After a mean radiological follow-up of eight (1–79) months, LC was observed in 83 (38.4%) patients and was not significantly influenced by BM count (p=0.064). After a mean OS after surgery of 12.7 (0–88) months, 120 (55.6%) patients had died. In univariate analysis, BM count showed no impact on OS (p=0.844), while age ≥/< 65 years (p=0.007), pre- and postoperative KPI ≥70 (p=0.002 and p=0.005, respectively), extra-cranial metastases (p=0.004), adjuvant radiation therapy (p<0.001), and adjuvant systemic treatment (p<0.001) did. In regression analysis the presence of extra-cranial metastases (HR 2.30 95%CI 1.53–3.48; p<0.001), adjuvant radiation therapy (HR 0.97 95%CI 0.23–0.86; p=0.016), and adjuvant systemic treatment (HR 0.37 95%CI 0.25–0.55; p<0.001) remained independent factors for survival. Conclusions The indication for resection of symptomatic BM in patients with NSCLC is justified even in case of multiple lesions to alleviate their neurological symptoms and to enable further treatment.

scholarly journals Survival after adjuvant radiation therapy in localized small cell lung cancer treated with complete resection

2019 ◽  
Vol 158 (6) ◽  
pp. 1665-1677.e2 ◽  
Author(s):  
Kathryn E. Engelhardt ◽  
Julia M. Coughlin ◽  
Malcolm M. DeCamp ◽  
Chadrick E. Denlinger ◽  
Shari L. Meyerson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Resection ◽  
Small Cell ◽  
Adjuvant Radiation ◽  
Small Cell Lung ◽  
Adjuvant Radiation Therapy

Resection of symptomatic non–small cell lung cancer brain metastasis in the setting of multiple brain metastases

2021 ◽  
pp. 1-7
Author(s):  
Stephanie T. Jünger ◽  
David Reinecke ◽  
Anna-Katharina Meissner ◽  
Roland Goldbrunner ◽  
Stefan Grau
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Systemic Treatment ◽  
Small Cell ◽  
Adjuvant Radiation ◽  
Small Cell Lung ◽  
Adjuvant Radiation Therapy ◽  
Adjuvant Systemic Treatment

OBJECTIVE Current guidelines primarily suggest resection of brain metastases (BMs) in patients with limited lesions. With a growing number of highly effective local and systemic treatment options, this view may be challenged. The purpose of this study was to evaluate the role of metastasectomy, disregarding BM count, in a comprehensive treatment setting. METHODS In this monocentric retrospective analysis, the authors included patients who underwent resection for at least 1 BM and collected demographic, clinical, and tumor-associated parameters. Prognostic factors for local control and overall survival (OS) were analyzed with the log-rank test and Cox proportional hazards analysis. RESULTS The authors analyzed 216 patients. One hundred twenty-nine (59.7%) patients were diagnosed with a single/solitary BM, whereas 64 (29.6%) patients had 2–3 BMs and the remaining 23 (10.6%) had more than 3 BMs. With resection of symptomatic BMs, a significant improvement in Karnofsky Performance Scale (KPS) was achieved (p < 0.001), thereby enabling adjuvant radiotherapy for 199 (92.1%) patients and systemic treatment for 119 (55.1%) patients. During follow-up, 83 (38.4%) patients experienced local recurrence. BM count did not significantly influence local control rates. By the time of analysis, 120 (55.6%) patients had died; the leading cause of death was systemic tumor progression. The mean (range) OS after surgery was 12.7 (0–88) months. In univariate analysis, the BM count did not influence OS (p = 0.844), but age < 65 years (p = 0.007), preoperative and postoperative KPS ≥ 70 (p = 0.002 and p = 0.005, respectively), systemic metastases other than BM (p = 0.004), adjuvant radiation therapy (p < 0.001), and adjuvant systemic treatment (p < 0.001) were prognostic factors. In regression analysis, the presence of extracranial metastases (HR 2.30, 95% CI 1.53–3.48, p < 0.001), adjuvant radiation therapy (HR 0.97, 95% CI 0.23–0.86, p = 0.016), and adjuvant systemic treatment (HR 0.37, 95% CI 0.25–0.55, p < 0.001) remained as independent factors for survival. CONCLUSIONS Surgery for symptomatic BM from non–small cell lung cancer may be indicated even for patients with multiple lesions in order to alleviate their neurological symptoms and to consequently facilitate further treatment.

Sign in / Sign up

Export Citation Format

Share Document